TABLE 1.
Subject demographics
| Study description | Subject description | Source | Sex
|
Mean (range) for:
|
||
|---|---|---|---|---|---|---|
| No. of males | No. of females | Age (yr) | Wt (kg) | |||
| Single oral and i.v. doses | Healthy volunteers | Ann Arbor, Mich.a | 13 | 7 | 32 (20–45) | 82 (64–111) |
| Repeated measures | Healthy volunteers | Ann Arbor, Mich.a | 8 | 4 | 38 (21–68) | 77 (51–119) |
| Multiple oral dose | Terminal cancer patients | Little Rock, Ark.b | 6 | 10 | 59 (44–73) | 77 (58–110) |
| Multiple i.v. dose | Terminal cancer patients | Little Rock, Ark.b | 7 | 4 | 60 (45–77) | 89 (73–128) |
| Neutropenic subjects | Patients treated for cancer | Houston, Tex.c | 5 | 4 | 45 (18–76) | 65 (51–93) |
a
A. Sedman, Community Research Clinic.
b
W. Tranum, Oncology Clinic.
c
K. Rolston, M. D. Anderson Cancer Center.